1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Canbridge Pharmaceuticals's 1-Year ROIIC % for the quarter that ended in Jun. 2024 was -56.78%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Canbridge Pharmaceuticals's 1-Year ROIIC % or its related term are showing as below:
HKSE:01228's 1-Year ROIIC % is ranked worse than 60.93% of 1413
companies
in the Biotechnology industry
Industry Median: -11.46
vs HKSE:01228: -56.78
Canbridge Pharmaceuticals 1-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Canbridge Pharmaceuticals's 1-Year ROIIC %
For the Biotechnology subindustry, Canbridge Pharmaceuticals's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canbridge Pharmaceuticals's 1-Year ROIIC % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Canbridge Pharmaceuticals's 1-Year ROIIC % falls into.
Canbridge Pharmaceuticals's 1-Year ROIIC % for the quarter that ended in Jun. 2024 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -413.558 (Jun. 2024) - -462.124 (Jun. 2023) )
/
( 202.648 (Jun. 2024) - 288.187 (Jun. 2023) )
=
48.566
/
-85.539
=
-56.78%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Canbridge Pharmaceuticals 1-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Canbridge Pharmaceuticals's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Canbridge Pharmaceuticals Inc is a biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01228 has been successfully added to your 